#ESMO25: Adding #immunotherapy to radiotherapy improved rates of pathological response in resectable #sarcoma, but #biomarkers and histology-focused trials are needed to further improve outcomes. Read more #ESMODailyReporter 📌 https://t.co/1IbgwtYLju @sandrapdangelo

#CTOS2025 is not only about great science, it's also a perfect opportunity for mentorship for trainees and young fellows! Don't miss the 🌅 Sunrise Mentorship Session on Nov 13, 7.00 am ( breakfast and coffee will be served ☕)! Check topics and mentors 🧑‍🏫on the graphic⬇️

During the session on novel targets and approaches, Sandra D’Angelo, MD (@sandrapdangelo) of @MSKCancerCenter discusses emerging T-cell therapies for sarcoma, highlighting current data, response mechanisms and future directions. Key Takeaways: ➡️ Afamicel and letecel show

After one patient's synovial sarcoma returned, a clinical trial led MSK helped shrink his tumors by 85%. That same #Tcell therapy is now approved by the @US_FDA. “This success story is just one example of MSK’s innovative approach to researching new treatments,” says MSK's

Wonderful colleague and collaborator!

Join sarcoma medical oncologist @sandrapdangelo TODAY for her session on "Development of Afami-Cel–Engineered Cell Therapy for Advanced Synovial" at @ASCO. #ASCO25 🗓️: 5/31 at 8:30am CT

CTOS President @SilviaStacchia is inviting everyone to join the Annual Meeting in Boca Raton and celebrate 30th Anniversary of the Society! Get ready and prepare your abstracts! Especially on the #sarcoma of the year 🌟#chondrosarcoma #CTOS2025 #CTOSTweeTOS

Had a great time visiting Regis today and speaking with students about recent advances in cancer research and my work in sarcoma treatment. Grateful for the warm welcome and thoughtful questions—future scientists in the making! #CancerResearch @RegisHighSchool @MSKCancerCenter

🎙️Dr. Sandra D’Angelo highlights the IGNYTE-ESO trial, where Lete-cel shows a 42% response rate in synovial sarcoma and MRCLS, advancing sarcoma care https://t.co/WnS7uKAr3o @sandrapdangelo @amalsargsyan #Cancer #MedEd #MedX #MedNews #Health #Medicine #OncoDaily #Oncology

Hear @sandrapdangelo of @MSKCancerCenter and @NamBuiMD of @StanfordCancer discuss developing targeted therapies that effectively address the SS18::SSX fusion oncogene and improving early detection methods. Watch more here: https://t.co/g6pmmLJtcg

Join us in Boulder, CO April 3, 2025 for inaugural Rocky Mountain #Sarcoma Symposium! incredible speakers @sandrapdangelo @JasonSicklick @GorlickRichard @RLRandallMD and Kaled Alektiar - register here: https://t.co/DQBLOzjZT6 time for ⛷️ afterwards! @CUCancerCenter

Thrilled to share our article this Thanksgiving Eve! 🍂 With expansion of HLA-restricted therapies, we show HLA genotyping via NGS is accurate, streamlines cancer care, boosts trial access, and may reduce disparities. Embedding it in routine panels is key! https://t.co/IRbbGV18KY

It's ok at #CTOS2024 to drag me to your poster to pitch your science for Clinical Cancer Research, it the most inspiring thing i get to do!!

The final countdown until #CTOS2024 meeting! 4 days full of great science and networking with #sarcoma experts - researchers, clinicians & patient advocates from around the world! If you can't join on-site, follow our social media and interact with colleagues using #CTOSTweeTOS

Phase 2 Study (JAVELIN Merkel 200): Biomarker analyses - avelumab for metastatic Merkel cell carcinoma. https://t.co/KCKxuiYtw9

Here’s a closer look at #JITC article: A multicenter, randomized, non-comparative, phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma: expansion cohorts & correlative analyses by @nathanseligson @bvantine1 @WTapMD @DrGarySchwartz @sandrapdangelo 1/6

Overview in @NatureBiotech discussing the recent landmark approval of the 1st #TCR gene therapy approval. Appreciate the opportunity to share our perspective alongside TCR aficionados including Phil Greenberg, @immatics and others. @MSKCancerCenter @MSK_DeptOfMed @parkerici

New #JITC article: A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses https://t.co/KWhO3ZTus4 @nathanseligson @sandrapdangelo

Afami-cel is now the first engineered cell therapy approved for a solid tumor, offering new hope for metastatic #synovialsarcoma patients. This marks a transformative moment in cancer care. https://t.co/RcbarFvDo2 @sandrapdangelo @MSKCancerCenter

FDA Grants Accelerated Approval to Afamitresgene Autoleucel (TECELRA) for Treating Advanced Synovial Sarcoma @sandrapdangelo @US_FDA @TheLancet https://t.co/DYpctjjWHl #Cancer #CancerCare #CellTherapy #FDA #OncoDaily #Oncology #Sarcoma #SolidTumor #Immunotherapy